New drug Leucettinib-21 enters first human safety trials

NCT ID NCT06206824

Completed Knowledge-focused Sponsor: Perha Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study is the first time Leucettinib-21 is being tested in humans. It aims to check the drug's safety and how the body processes it. The trial includes healthy volunteers and people with Down syndrome or Alzheimer's disease. No treatment benefit is expected at this early stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Down syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE DOWN SYNDROME HEALTHY VOLUNTEERS

Contacts and locations

Locations

Eurofins Optimed

Gières, 38610, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.